Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.

PMID:
14707788
[PubMed - indexed for MEDLINE]
2.

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.

AIDS. 2004 Jul 23;18(11):1529-37.

PMID:
15238771
[PubMed - indexed for MEDLINE]
3.

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ.

Antimicrob Agents Chemother. 2004 Jan;48(1):116-23.

PMID:
14693528
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.

PMID:
16420253
[PubMed - indexed for MEDLINE]
5.

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.

Sáez-Llorens X, Nelson RP Jr, Emmanuel P, Wiznia A, Mitchell C, Church JA, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S.

Pediatrics. 2001 Jan;107(1):E4.

PMID:
11134468
[PubMed - indexed for MEDLINE]
6.

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C; CNA3007 Study Group.

Antivir Ther. 2003 Apr;8(2):163-71.

PMID:
12741629
[PubMed - indexed for MEDLINE]
7.

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R, Clendeninn N; Virqacept Collaborative Study Group.

AIDS. 2001 Oct 19;15(15):1971-8.

PMID:
11600825
[PubMed - indexed for MEDLINE]
8.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255
[PubMed - indexed for MEDLINE]
9.

Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.

Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L.

Antivir Ther. 2000 Sep;5(3):215-25.

PMID:
11075942
[PubMed - indexed for MEDLINE]
10.

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team.

AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231.

PMID:
19320570
[PubMed - indexed for MEDLINE]
12.

Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.

Sension MG, Bellos NC, Johnson J, Sepulveda GE, DeJesus E, Santana JL, Ames MH, Goodwin SD.

HIV Clin Trials. 2002 Sep-Oct;3(5):361-70.

PMID:
12407485
[PubMed - indexed for MEDLINE]
13.

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G.

AIDS. 1998 Nov 12;12(16):F197-202.

PMID:
9833847
[PubMed - indexed for MEDLINE]
14.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team.

BMC Infect Dis. 2003 Jun 10;3:10.

PMID:
12795812
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

Clin Ther. 2006 May;28(5):745-54.

PMID:
16861096
[PubMed - indexed for MEDLINE]
16.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team.

JAMA. 2001 Mar 7;285(9):1155-63. Erratum in: JAMA 2001 Jun 13;285(22):2858.

PMID:
11231744
[PubMed - indexed for MEDLINE]
17.

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

Haubrich R, Thompson M, Schooley R, Lang W, Stein A, Sereni D, van der Ende ME, Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N.

AIDS. 1999 Dec 3;13(17):2411-20.

PMID:
10597783
[PubMed - indexed for MEDLINE]
18.

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team.

AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2.

PMID:
19542866
[PubMed - indexed for MEDLINE]
19.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
[PubMed - indexed for MEDLINE]
20.

Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.

Nadal D, Steiner F, Cheseaux JJ, Lazarevitch CA, Aebi C, Kind C, Rudin C.

Infection. 2000 Sep;28(5):287-96. Erratum in: Infection 2000 Nov-Dec;28(6):402.

PMID:
11073135
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk